| Literature DB >> 30431161 |
Paola Gruarin1, Stefano Maglie1, Marco De Simone1, Barbara Häringer2,3, Chiara Vasco1, Valeria Ranzani1, Roberto Bosotti1, Johanna S Noddings1, Paola Larghi1, Federica Facciotti1, Maria L Sarnicola1, Martina Martinovic1, Mariacristina Crosti1, Monica Moro1, Riccardo L Rossi1, Maria E Bernardo4, Flavio Caprioli5, Franco Locatelli4, Grazisa Rossetti1, Sergio Abrignani1,6, Massimiliano Pagani1,7, Jens Geginat1.
Abstract
Whether human IL-10-producing regulatory T cells ("Tr1") represent a distinct differentiation lineage or an unstable activation stage remains a key unsolved issue. Here, we report that Eomesodermin (Eomes) acted as a lineage-defining transcription factor in human IFN-γ/IL-10 coproducing Tr1-like cells. In vivo occurring Tr1-like cells expressed Eomes, and were clearly distinct from all other CD4+ T-cell subsets, including conventional cytotoxic CD4+ T cells. They expressed Granzyme (Gzm) K, but had lost CD40L and IL-7R expression. Eomes antagonized the Th17 fate, and directly controlled IFN-γ and GzmK expression. However, Eomes binding to the IL-10 promoter was not detectable in human CD4+ T cells, presumably because critical Tbox binding sites of the mouse were not conserved. A precommitment to a Tr1-like fate, i.e. concominant induction of Eomes, GzmK, and IFN-γ, was promoted by IL-4 and IL-12-secreting myeloid dendritic cells. Consistently, Th1 effector memory cells contained precommitted Eomes+ GzmK+ T cells. Stimulation with T-cell receptor (TCR) agonists and IL-27 promoted the generation of Tr1-like effector cells by inducing switching from CD40L to IL-10. Importantly, CD4+ Eomes+ T-cell subsets were present in lymphoid and nonlymphoid tissues, and their frequencies varied systemically in patients with inflammatory bowel disease and graft-versus-host disease. We propose that Eomes+ Tr1-like cells are effector cells of a unique GzmK-expressing CD4+ T-cell subset.Entities:
Keywords: Differentiation; EOMES; Granzyme K; Regulatory T cells; Th17
Mesh:
Substances:
Year: 2018 PMID: 30431161 DOI: 10.1002/eji.201847722
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532